COGNITION THERAPEUTICS INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that COGNITION THERAPEUTICS INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($23.49M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($33.97M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($25.79M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($21.40M) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($11.72M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($7.84M) | Mar 30, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($47.80M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($53.97M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($50.72M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($43.55M) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($28.60M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($17.41M) | Mar 30, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $37.19M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $41.68M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $37.20M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $30.32M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $18.57M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $12.89M | Mar 30, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($24.59M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($28.47M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($16.02M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($18.53M) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($3.63M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($3.43M) | Mar 30, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $4.0K | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $147.0K | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $171.0K | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $27.0K | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $10.0K | Mar 30, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $48.39M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $30.23M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $35.16M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $50.43M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $59.14M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $7.12M | Mar 30, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.12M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $11.48M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $10.69M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $10.18M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $7.86M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $19.93M | Mar 30, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $34.27M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $18.75M | Mar 26, 2026 |
| FY2025 | Dec 31, 2023 | $24.47M | Mar 26, 2026 |
| FY2024 | Dec 31, 2022 | $40.25M | Mar 20, 2025 |
| FY2023 | Dec 31, 2021 | $51.27M | Mar 26, 2024 |
| FY2022 | Dec 31, 2020 | ($68.18M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2019 | ($58.42M) | Mar 30, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($198.65M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($175.16M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($141.19M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($115.40M) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($94.00M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($68.22M) | Mar 30, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $36.81M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $25.01M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $29.92M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $41.56M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $54.72M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $5.19M | Mar 30, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | (3) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | (23) | Mar 30, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | (3) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | (23) | Mar 30, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 88.90M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 59.85M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 32.17M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | 28.99M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | 22.23M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | 538,793 | Mar 30, 2022 |